BIW-8962

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBIW-8962
Drug Alias NameAnti-GM2 humanised antibody-Kyowa Hakko KirinBIW-8962
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsGM2(ganglioside M2) inhibitors
TargetsGM2(ganglioside M2)
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungMultiple Myeloma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiowa IncKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyowa Hakko Kirin Pharma IncKyowa Kirin Co LtdKyowa Kirin Korea Co Ltd
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungMultiple Myeloma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A